At a Glance
- Companies: IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A); Biomia ApS
- Location: Gothenburg, Sweden (IRLAB); Denmark (Biomia)
- Deal value: Undisclosed; Biomia funds ISP evaluation studies
- Focus area: ML/AI phenotypic screening of small‑molecule CNS compounds
- Next steps: Characterise novel chemistries for undisclosed CNS indications
What happened?
IRLAB Therapeutics AB has entered a collaboration agreement with Danish biotech Biomia ApS to evaluate Biomia’s novel small‑molecule drug candidates using IRLAB’s proprietary Integrative Screening Process (ISP) platform. Biomia will supply compounds and fund studies conducted by IRLAB’s ML/AI‑supported technology.
Why does it matter?
ISP combines phenotypic screening with machine learning to identify novel drug candidates with blockbuster potential across CNS disorders, validated by IRLAB’s Parkinson’s pipeline (mesdopetam, pirepemat, IRL757). Biomia’s unique lead identification and synthesis complements ISP’s ability to predict indications and differentiate from existing treatments.
Who’s behind it?
IRLAB discovers Parkinson’s therapies using ISP, with mesdopetam (phase III‑ready for dyskinesia), pirepemat (phase IIb falls), IRL757 (phase I apathy) and preclinical IRL942/IRL1117. Biomia develops novel CNS chemistries requiring advanced phenotypic characterisation.
How was it achieved?
IRLAB applies ISP for in‑depth compound profiling, target indication prediction and competitive differentiation across undisclosed CNS areas. Biomia finances the work, gaining actionable insights for portfolio prioritisation.
What’s next?
Detailed ISP results will guide Biomia’s next development steps; successful validation could lead to expanded collaboration or licensing. IRLAB continues Parkinson’s advancement while showcasing ISP’s platform utility.
What are people saying?
IRLAB CEO Kristina Torfgård: “ISP has proven its ability for discovery of entirely novel drug candidates… Biomia’s strategy makes a good match with our platform.”